TAOX
TAO シナジー
TAO Synergies Inc.
閉場中RVOL 0.7xDV $164,85420日平均DV $235,237?
Earnings 2026-12-0252W high -76.3%52W low +9.7%Market cap $15MAvg volume 127K
Company Overview
TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.
Earnings & Financials
Earnings actuals
| Period | EPS | Revenue | FCF |
|---|
| 2026 Q2 | -1.83 | $88,626 | -$874,980 |
| 2026 Q1 | 0.45 | $388,774 | -$2M |
| 2025 Q4 | -1.04 | $91,728 | -$2M |
| 2025 Q3 | -1.56 | $203,371 | -$1M |
| 2025 Q2 | -11.26 | $3,962 | -$749,072 |
| 2025 Q1 | 0.12 | $0 | -$2M |
|
Beta access -> Sign in with an invite code